Table of Contents substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. We are unable to currently estimate these costs with any degree of certainty. We also expect these new rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage previously available. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers. Our failure to raise additional capital or generate the cash flows necessary to expand our operations and invest in our services could reduce our ability to compete successfully. We may need to raise additional funds, and we may not be able to obtain additional debt or equity financing on favorable terms, if at all. If we raise additional equity financing, our stockholders may experience significant dilution of their ownership interests, and the per share value of our common stock could decline. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness and force us to maintain specified liquidity or other ratios. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things: develop or enhance our services; continue to expand our development, sales and marketing organizations; acquire complementary technologies, products or businesses; expand our operations, in the United States or internationally; hire, train and retain employees; or respond to competitive pressures or unanticipated working capital requirements. An active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public offering price. Prior to this offering, there has been no public market for shares of our common stock. Although our common stock has been approved for listing on The NASDAQ Global Market, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock will be determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after the offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell. Our stock price may be volatile, and the market price of our common stock after this offering may drop below the price you pay. The market price of our common stock could be subject to significant fluctuations after this offering, and it may decline below the initial public offering price. Market prices for securities of early stage companies have historically been particularly volatile. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. Some of the factors that may cause the market price of our common stock to fluctuate include: fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; fluctuations in our recorded revenue, even during periods of significant sales order activity; changes in estimates of our financial results or recommendations by securities analysts; failure of any of our services to achieve or maintain market acceptance; changes in market valuations of similar companies;

Per Share Weighted Average Estimated Fair Value of Options(3)
Number of Shares Subject to Options Granted
Per Share Exercise Price of Options(1)
Per Share Estimated Fair Value of Common Stock(2)
April 27, 2006 July 20, 2006 October 26, 2006 January 24, 2007 April 27, 2007 August 3, 2007 November 5, 2007 November 21, 2007 January 17, 2008 April 18, 2008(4) July 17, 2008 October 23, 2008 February 5, 2009 May 7, 2009
8,000 396,400 118,000 659,000 94,000 69,000 100,000 498,000 214,000 53,800 95,000 22,000 58,000 10,800
$ 1.25 $ 1.25 $ 1.25 $ 1.25 $ 1.25 $ 9.28 $ 9.65 $ 9.65 $10.75 $11.40 $11.40 $11.78 $10.08 $12.10
$ 0.88 $ 0.88 $ 0.88 $ 2.73 $ 5.60 $ 8.65 $ 9.65 $ 9.35 $10.75 $11.23 $11.25 $11.78 $10.08 $12.10
$0.55 $0.58 $0.55 $2.20 $5.05 $6.65 $7.43 $7.35 $7.60 $8.10 $7.75 $7.98 $6.75 $8.18
(1) The per share exercise price of options represents the exercise price as determined by our board of directors on the date of the grant. (2) The per share estimated fair value of common stock represents the determination by our board of directors of the fair value of our common stock as of the date of grant, taking into account various objective and subjective factors and including the results, if applicable, of valuations of our common stock by an independent valuation specialist. (3) The per share weighted average estimated fair value of options was estimated for the date of grant using the Black-Scholes options pricing model. (4) Excludes the modification on April 18, 2008 related to stock options previously granted on April 27, 2007 to increase the exercise price from $1.25 per share to $5.60 per share. Based on the midpoint of the price range as set forth on the cover of this prospectus, the aggregate intrinsic value of our vested outstanding stock options as of March 31, 2009 was $22.8 million and the aggregate intrinsic value of our unvested outstanding stock options as of March 31, 2009 was $11.9 million. Our board of directors has historically estimated the fair value of our common stock, with input from management, as of the date of each stock option grant. Because there has been no public market for our common stock, our board of directors determined the fair value of our common stock by considering a number of objective and subjective factors including: the original sale price of common stock prior to any preferred stock financing rounds, which was $1.25 per share of common stock; the per share value of any preferred stock financing rounds and the amount of redeemable convertible preferred stock liquidation preferences, including any additional fund-raising activities that may have occurred in the period; any third-party trading activity in our common stock and the illiquid nature of our common stock, including the opportunity for any liquidity events; our size and historical operating and financial performance, including our updated operating and financial projections; achievement of enterprise milestones; the stock price performance of a peer group comprised of selected publicly-traded companies identified as being comparable to us; and trends in the broad market for software and other technology stocks. Our board of directors considered and applied these and other factors in determining an estimate of the fair value of our common stock on each stock option grant date. Additionally, beginning in August 2006, our board of directors engaged Shields & Company, or Shields, an independent valuation specialist, to prepare third-party independent valuations of our common stock. Shields initial valuation report, as described in detail below, was as of July 31, 2006 and was used by our board of directors to estimate the fair value of our common stock as of October 26, 2006, the first option grant date after the initial valuation report. Additionally, the July 31, 2006 valuation report was also initially used to estimate the fair value of our common stock for the January 24, 2007 and April 27, 2007 stock option grants. However, in December 2007 and in connection with our proposed initial public offering, our board of directors undertook a reassessment of the fair value of our common stock as of each option grant date during 2007. As part of that reassessment, our board of directors obtained from Shields retrospective fair market valuation reports for each option grant date during 2007. The retrospective valuations, as described in detail below for each option grant date, have been used to estimate the fair value of our common stock as of each option grant date in 2007 and in calculating stock-based compensation expense.

Table of Contents Our Solutions Our solutions allow our users to remotely access, support and manage computers and other Internet-enabled devices on demand. We believe our solutions benefit users in the following ways: Reduced set-up, support and management costs. Our services enable IT staff to administer, monitor and support computers and other Internet-enabled devices at a remote location. Businesses easily set up our on-demand services with little or no modification to the remote locations network or security systems and without the need for upfront technology or software investment. In addition, our customers lower their support and management costs by performing management-related tasks remotely, reducing or eliminating the costs of on-site support and management. Increased mobile worker productivity. Our remote-access services allow non-technical users to access and control remote computers and other Internet-enabled devices, increasing their mobility and allowing them to remain productive while away from the office. Increased end-user satisfaction. Our customers rely on our on-demand services to improve the efficiency and effectiveness of end-user support. Satisfaction with support services is primarily measured by call-handling time and whether or not the problem is resolved on the first call. Our services enable help desk technicians to quickly and easily gain control of a remote users computer. Once connected, the technician can diagnose and resolve problems while interacting with and possibly training the end user. By using our solutions to support remote users, our customers have reported increased user satisfaction while reducing call handling time by as much as 50% over phone-only support. Reliable, fast and secure service. Our service possesses built-in redundancy of servers and other infrastructure in three data centers, two located in the United States and one located in Europe. Our proprietary platform enables our services to connect and manage devices at enhanced speeds. Our services implement industry-standard security protocols and authenticate and authorize users of our services without storing passwords. Easy to try, buy and use. Our services are simple to install, which allows our prospective customers to use our services within minutes of registering for a trial. Our customers can use our services to manage their remote systems from any Web browser. In addition, our low service-delivery costs and hosted delivery model allow us to offer each of our services at competitive prices and to offer flexible payment options. Our premium services range in list price from approximately $30 to $1,900 per year. Our Competitive Strengths We believe that the following competitive strengths differentiate us from our competitors and are key to our success: Large established user community. As of March 31, 2009, over 22.1 million registered users have connected over 70 million Internet-enabled devices to a LogMeIn service. During the quarter ended March 31, 2009, the number of connected devices grew at an average of approximately 95,000 new devices per day. These users drive awareness of our services through personal recommendations, blogs and other online communication methods and provide us with a significant audience to which we can market and sell premium services. Efficient customer acquisition model. We believe our free products and our large installed user base help to generate word-of-mouth referrals, which in turn increases the efficiency of our paid marketing activities, the large majority of which are focused on pay-per-click search engine advertising. Sales of our premium services are generated through word-of-mouth referrals, Web-based advertising, expiring free trials that we convert to paying customers and marketing to our existing customer and user base. During the year ended 2008 and the three months ended March 31, 2009, we estimate that approximately 50% of our new paying customers were generated through word-of-mouth referrals and that approximately 25% of new customers added in the year ended 2008 and three months ended March 2009 found LogMeIn by searching the Internet for remote access solutions. We believe this

Name Bonus Payments Option Awards ($)(1) Total ($)
David E. Barrett Steven J. Benson Kenneth D. Cron Edwin J. Gillis Irfan Salim

228,375(2)

331,441(3) 213,458(4) 62,146(5)

559,816 213,458 62,146

(1) Represents the dollar amount of share-based compensation expense recognized for financial statement reporting purposes pursuant to SFAS 123R during 2008, except that such amounts do not reflect an estimate of forfeitures related to servicebased vesting conditions. The assumptions used by us with respect to the valuation of option grants are set forth in Note 12 to our financial statements included elsewhere in this prospectus.
Table of Contents (2) Represents a one-time bonus payment paid in connection with our amendment of stock options to increase the exercise price of such options. See Certain Relationships and Related Transactions Stock Issuances and Related Matters for more information. (3) Represents an option to purchase 60,000 shares of our common stock with an exercise price of $1.25 per share. The exercise price per share of this option was modified to $5.60 per share in April 2008. (4) Represents an option to purchase 60,000 shares of our common stock with an exercise price of $9.65 per share. (5) Represents an option to purchase 60,000 shares of our common stock with an exercise price of $1.25 per share and an option to purchase 30,000 shares of our common stock with an exercise price of $11.40 per share. In June 2009, our board of directors approved a compensation program, which will become effective upon the closing of this offering, pursuant to which we will pay each non-employee director an annual retainer of $20,000 for service as a director. Each non-employee director will receive an additional annual fee of $5,000 for service on the audit committee, $3,750 for service on the compensation committee and $2,500 for service on the nominating and corporate governance committee. The chairman of the audit committee will receive an additional annual retainer of $10,000, the chairman of the compensation committee will receive an additional annual retainer of $7,500, and the chairman of the nominating and corporate governance committee will receive an additional annual retainer of $5,000. We will reimburse each non-employee member of our board of directors for out-of-pocket expenses incurred in connection with attending our board and committee meetings. In addition, pursuant to our 2009 stock incentive plan, each non-employee director will receive an option to purchase 60,000 shares of our common stock upon his or her initial appointment to our board of directors. Each non-employee director will also receive an option grant to purchase 30,000 shares of our common stock at every other annual meeting, provided that such non-employee director has served on our board of directors for at least 18 months and continues to serve as a director after such annual meeting. Each of these options will vest as to 12.5% of the shares underlying the option every three months after the date of grant, subject to the non-employee directors continued service as a director. The exercise price of these options will equal the fair market value of our common stock on the date of grant. In the event of a change of control, the vesting schedule of these options will accelerate in full. Executive Compensation Compensation Discussion and Analysis Overview The compensation committee of our board of directors oversees our executive compensation program. In this role, the compensation committee reviews and approves annually all compensation decisions relating to our named executive officers. Our historical executive compensation programs were developed and implemented by our board of directors and compensation committee consistent with practices of other venture-backed, privately-held companies. Prior to this offering, our compensation programs, and the process by which they were developed, were less formal than that typically employed by a public company. During this time, our board of directors and compensation committee generally established and benchmarked our executive compensation on an informal basis by considering the employment and compensation history of each executive and comparing our executives compensation to our estimates, based on the experience of our board members in the industry and in establishing executive compensation, research of pay practices at other venture-backed companies informally conducted by board members, and external compensation databases such as Salary.com, of executive compensation paid by companies in our industry and region. The board of directors and the compensation committee intend to continue to formalize their approach to the development and implementation of our executive compensation programs.

Table of Contents are made from time to time in the discretion of our board of directors or compensation committee consistent with our incentive compensation program objectives. It is anticipated that following the completion of this offering, our board of directors will consider implementing a grant date policy for our executive officers. We do not have any equity ownership guidelines for our executives. Change of Control Benefits. Pursuant to employment offer letters and our stock incentive plans, our executives are entitled to specified benefits in the event of the termination of their employment under specified circumstances, including termination following a change of control of our company. We have provided more detailed information about these benefits, along with estimates of their value under various circumstances, in the Potential Payments Upon Termination or Change of Control section of this prospectus. Fifty percent of all unvested awards automatically accelerate and vest in full in the event of a change of control. In addition, we have provided certain executives, including Messrs. Simon, Anka, Kelliher and Ms. Meyers, with full acceleration and vesting of all awards in the case of change-of-control and a termination of the employment of the executive, other than for cause, in connection with such change of control, sometimes called a double trigger. Accordingly, these extra benefits are paid only if the employment of the executive is terminated during a specified period after the change of control. We believe this double trigger benefit improves stockholder value because it prevents an unintended windfall to executives in the event of a friendly change of control, while still providing them appropriate incentives to cooperate in negotiating any change of control in which they believe they may lose their jobs. We believe providing these benefits helps us compete for executive talent. We believe that our change of control benefits are generally in line with severance packages offered to executives in our industry and region. Insurance, retirement and other employee benefits and compensation. We offer benefits that are provided to all employees, including health and dental insurance, life and disability insurance, a 401(k) plan, an employee assistance program, maternity and paternity leave plans and standard company holidays to our U.S. employees. Our executive officers are eligible to participate in all of our employee benefit plans, in each case on the same basis as other employees. Summary Compensation Table The following table sets forth information regarding compensation earned by our president and chief executive officer, our chief financial officer and each of our three other most highly compensated executive officers during the applicable years. We refer to these executive officers as our named executive officers elsewhere in this prospectus.

1/17/2008
Future Payouts Under Non-Equity Incentive Plan Awards Target ($)(1)
$ 60,000 45,000 49,000 105,000 38,000
Exercise or Base Price of Option Awards ($/Sh)(2)

$10.75

Grant Date Fair Value of Stock and Option Awards(3)

$755,000

(1) Cash bonuses paid under the cash incentive bonus program for 2008 are also disclosed in the Summary Compensation Table. (2) For a discussion of our methodology for determining the fair value of our common stock, see the Managements Discussion and Analysis of Financial Condition and Results of OperationsCritical Accounting Policies section of this prospectus. (3) Valuation of these options is based on the aggregate dollar amount of share-based compensation recognized for financial statement reporting purposes computed in accordance with SFAS 123R over the term of these options, excluding the impact of estimated forfeitures related to service-based vesting conditions. The assumptions used by us with respect to the valuation of stock and option awards are set forth in Note 12 to our financial statements included elsewhere in this prospectus. (4) The shares subject to this option vest annually over a four year period, subject to acceleration of vesting in the event of a change of control of our company as further described in the Management Employment Agreement and Management Potential Payments Upon Termination or Change of Control sections of this prospectus.
Outstanding Equity Awards at Fiscal Year End The following table sets forth information regarding outstanding equity awards as of December 31, 2008 held by our named executive officers.
Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)
Number of Securities Underlying Unexercised Options (#) Exercisable
Number of Securities Underlying Unexercised Options (#) Unexercisable
Option Exercise Price ($)

Option Expiration Date

Michael K. Simon

Table of Contents Singapore This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the SFA), (ii) to a relevant person, or any person pursuant to Section 275 (1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Where the shares are subscribed or purchased under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole whole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries rights and interest in that trust shall not be transferable for six months after that corporation or that trust has acquired the shares under Section 275 except: (i) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA; (ii) where no consideration is given for the transfer; or (iii) by operation of law. By accepting this prospectus, the recipient hereof represents and warrants that he is entitled to receive it in accordance with the restrictions set forth above and agrees to be bound by limitations contained herein. Any failure to comply with these limitations may constitute a violation of law.
LEGAL MATTERS The validity of the shares of common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and Dorr LLP, Boston, Massachusetts. The underwriters are represented by Ropes & Gray LLP, Boston, Massachusetts. EXPERTS The consolidated financial statements as of December 31, 2008 and 2007, and for each of the three years in the period ended December 31, 2008, included in this Prospectus have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein (which report expresses an unqualified opinion on the consolidated financial statements and includes an explanatory paragraph refering to the adoption of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, effective January 1, 2007). Such financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. Shields & Company, Inc., an independent valuation firm, has performed valuations of the fair value of our common stock. Shields & Company, Inc. has consented to the references to its valuation reports in this prospectus. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the exhibits, schedules and amendments to the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of theses statements is qualified in all respects by this reference. You may read and copy the registration statement of which this prospectus is a part at the SECs public reference room, which is located at 100 F Street, N.E., Room 1580, Washington, DC 20549. You can request copies of the registration statement by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the SECs public reference room. In addition, the SEC maintains an Internet website, which is located at http://www.sec.gov, that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SECs Internet website. Upon completion of this offering, we will be subject to the information reporting requirements of the Securities Exchange Act of 1934, and we will file reports, proxy statements and other information with the SEC. This prospectus includes statistical data that were obtained from industry publications. These industry publications generally indicate that the authors of these publications have obtained information from sources believed to be reliable but do not guarantee the accuracy and completeness of their information. While we believe these industry publications to be reliable, we have not independently verified their data.

Number of Shares Subject to Options Granted Per Share Exercise Price of Option Est. Fair Value of Common Stock(1) Weighted Ave Est. Fair Value of Option(2)
April 27, 2006 July 20, 2006 October 26, 2006 January 24, 2007 April 27, 2007 August 3, 2007 November 5, 2007 November 21, 2007 January 17, 2008 April 18, 2008(3) July 17, 2008 October 23, 2008 February 5, 2009
8,000 396,400 118,000 659,000 94,000 69,000 100,000 498,000 214,000 53,800 95,000 22,000 58,000
$ 1.25 $ 1.25 $ 1.25 $ 1.25 $ 1.25 $ 9.28 $ 9.65 $ 9.65 $10.75 $11.40 $11.40 $11.78 $10.08
$ 0.88 $ 0.88 $ 0.88 $ 2.73 $ 5.60 $ 8.65 $ 9.65 $ 9.35 $10.75 $11.23 $11.25 $11.78 $10.08
$0.55 $0.58 $0.55 $2.20 $5.05 $6.65 $7.43 $7.35 $7.60 $8.10 $7.75 $7.98 $6.75
Table of Contents (1) The per share estimated fair value of common stock represents the determination by our Board of Directors of the fair value of our common stock on the date of grant, as determined taking into account our most recent available independent common stock valuation (2) The per share estimated fair value of option was estimated at grant date using the Black-Scholes option pricing model (3) Excludes the modification on April 18, 2008 to stock options previously granted on April 27, 2007 to increase the exercise price to $5.60 per share. The Company uses the Black-Scholes option-pricing model to estimate the grant date fair value of stock option grants. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the options expected term. The Company estimates expected term based on historical exercise activity and giving consideration to the contractual term of the options, vesting schedules, employee turnover, and expectation of employee exercise behavior. The assumed dividend yield is based upon the Companys expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the estimated life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Historical employee turnover data is used to estimate pre-vesting option forfeiture rates. The compensation expense is amortized on a straight-line basis over the requisite service period of the options, which is generally four years. The Company used the Black-Scholes option-pricing model to estimate the grant date fair value of stock option grants. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the options expected term. The Company estimates expected term based on historical exercise activity and giving consideration to the contractual term of the options, vesting schedules, employee turnover, and expectation of employee exercise behavior. The assumed dividend yield is based upon the Companys expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the estimated life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Historical employee turnover data is used to estimate pre-vesting option forfeiture rates. The compensation expense is amortized on a straight-line basis over the requisite service period of the options, which is generally four years. The Company used the following assumptions to apply the Black-Scholes option-pricing model:

Cost of revenue Research and development Selling and marketing General and administrative
2,008 5,130 28,394 26,535 62,067
10,283 105,030 177,035 222,220 $ 514,568
63,580 418,683 962,302 1,304,360 $ 2,748,925
13,081 101,275 207,173 277,611 599,140
14,326 81,224 219,640 292,988 608,178
As of December 31, 2008 and March 31, 2009, there was approximately $6,436,000 and $5,781,000 of total unrecognized share-based compensation cost, net of estimated forfeitures, related to unvested stock option grants which are expected to be recognized over a weighted average period of 1.5 and 1.3 years. The total unrecognized share-based compensation cost will be adjusted for future changes in estimated forfeitures. Of the total stock options issued subject to the Plans, certain stock options have performance-based vesting. These performance-based options granted during 2004 and 2007 were generally granted at-the-money, contingently vest over a period of two to four years depending upon the nature of the performance goal, and have a contractual life of ten years. These performance-based options are summarized below:
Number of Shares Options Weighted Average Exercise Price Remaining Contractual Term (Yrs.) Aggregate Intrinsic Value
Outstanding, January 1, 2008 Granted Exercised Forfeited Outstanding, December 31, 2008 Granted (unaudited) Exercised (unaudited) Forfeited (unaudited) Outstanding, March 31, 2009 (unaudited) Exercisable at December 31, 2008 Exercisable at March 31, 2009 (unaudited) Options vested or expected to vest at December 31, 2008(1) Options vested or expected to vest at March 31, 2009 (unaudited)(1)
718,718,718,000 493,000 538,000 718,000 718,000

$5,815,800

7,556,950

1.25 1.25 1.25 1.25 1.25

6.3 6.0 5.7 6.5 6.2
6,336,350 5,188,825 4,747,850 7,556,950 6,336,350
(1) In addition to the vested options, the Company expects a portion of the unvested options to vest at some point in the future. Options expected to vest is calculated by applying the result of an estimated performance option forfeiture rate to the unvested options. The aggregate intrinsic value was calculated based on the positive differences between the estimated fair value of the Companys common stock on December 31, 2007 and 2008, of $9.35 and $11.78 per share, respectively, and $10.08 per share on March 31, 2009, and the exercise price of the options.

4.2 Ownership of Joint Components. In accordance with Section 7.3, LMI and Intel shall jointly own all rights, title and interest (including all intellectual property rights) in any and all Joint Components. 5. MANAGEMENT OF COMPONENTS. 5.1 Delay In Delivery/Performance. No Party shall be liable for any performance failure, delay in performance, or lost data under this Agreement (other than for delay in the payment of money due and payable hereunder) to the extent said failures or delays are proximately caused by the failure of the other Party (including, without limitation, failure of suppliers, subcontractors and carriers) to perform its obligations under this Agreement or to provide the reasonably necessary information, support, functionality, service or Component required by the Party experiencing the difficulty, provided that in any such event, as a condition to the claim of non-liability, the Party experiencing the difficulty shall give the other written notice, with full details following the occurrence of the cause relied upon. 5.2 Reports on Progress. The Parties shall, from time to time as reasonably requested by the other Party (but no more often than monthly), provide reports related to performance and delivery of the Components. 5.3 Notifications of Complaints. The Parties shall promptly notify the other Party in writing of any material complaints or claims made by or through any customer, third-party or governmental or regulatory body regarding the Components or any support given in connection with the Components. 5.4 Account Management. Each Party agrees to assign an account manager to facilitate the communication between the Parties and to monitor the progression of each Partys obligations under the Agreement. The assignment of each account manager will be in the sole discretion of the assigning Party. Each Party, through the account managers, agrees to monthly meetings and/or conference calls to review the status of the Solution and the other obligations under the Agreement and address any issues that might arise. 6 LICENSES AND OTHER RIGHTS 6.1 Intel Rights. LMI hereby grants Intel the specific nontransferable (subject to Section 14 hereof) license and other rights regarding the specific items described on Schedule 6A , subject to all of the limitations and restrictions contained in this Agreement, Schedule 6A and the other Schedules and Exhibits contained herein. 6.2 LMI Rights. Intel hereby grants LMI a nontransferable (subject to Section 14 hereof), nonexclusive, royalty-free, end-user license, without the right to sublicense (the LMI License ) to use the Intel Components, and the items listed on Schedule 3A solely in connection with accessing or connecting to personal computers and servers for the purposes specifically described in this Agreement and only during the Term of this Agreement, subject to the restrictions contained herein, including the following: (a) LMI shall not, for itself, any affiliate of LMI or any third party decompile, disassemble, or reverse engineer the Intel Components; (b) except as specifically permitted in this Agreement, LMI shall not modify, port, translate, localize or create derivative works from the Intel Components or any items subject to the LMI License; and (c) LMI shall not alter, copy or duplicate any aspect of the Intel Components, except as expressly permitted by Intel in a written authorization signed by a duly authorized officer of Intel. LMI acknowledges that its rights hereunder are those of a licensed user and that the Intel 3

SCHEDULE 8E Service And Response Level 1) Availability Schedule. LMI shall seek to make the Solution available at least [**] percent ([**]%) of the time in any quarter, each as measured over 24 hour period of all days during such quarters and excluding those periods of time designated as scheduled Downtime (as defined below) and Downtime not attributable to maintenance, system freezes or the Other Activities described below, with the following performance standards: a) Scheduled Downtime and Maintenance Activities that Impact Availability. Regularly scheduled Downtime and maintenance activities may cause a service outage or adversely affect performance (such as slow response time). LMI will make reasonable efforts to perform such activities between 9:00 pm and 4:00 am, Monday through Friday or 8:00 PM to 8:00 AM Saturday, Sunday and Holidays, all Eastern United States Time. Other Activities that Impact Service Availability. In addition to regularly scheduled Downtime and maintenance activities, LMI may perform other required upgrade, testing and maintenance work or modifications after providing a minimum of forty eight (48) hours notice to Intel. LMI may also perform at any time any upgrade, testing, maintenance or corrections.
3) Initial Response; Service Restoration; Defect Resolution. With respect to the terms utilizes in the table below, the following definitions shall apply: a) b) Initial Response means the time it takes from Intels initial report of the defect until Intel speaks with the appropriate LMI subject matter expert. The measurement of Initial Response time does not apply when an Intel call is related to a previously reported defect. Service Restoration (SLA) means the time it takes LMI to apply a functional resolution to the reported defect, meaning LMI provides Intel with a temporary fix or workaround that solves a reported Defect and that can be used by Intel with minimal inconvenience and minimal impact on Intels business operations. Defect Resolution is the time elapsed from Intels report of a defect to the time LMI provides a final correction or modification for the Solution that corrects the root cause of the defect.
The Parties agree that the time frames for Initial Response, Service Restoration and Defect Resolution set forth in the following table represent the outside time limit for Initial Response, Service Restoration and Defect Resolution. 40

property rights to the Feedback to incorporate or otherwise utilize Feedback as provided by LMI to Intel in the design of Intel products and to design, debug, display, perform, copy, make, have made, use, sell, and otherwise dispose of and support Intels and its sublicensees products and documentation embodying such Feedback in any manner and via any media Intel chooses. Any and all Feedback shall be considered the Confidential Information of LMI and the confidentiality provisions referenced at Section 11 apply to any Feedback, except to the extent reasonably necessary for Intel to implement the Feedback provided by LMI hereunder (even in this event Intel will use commercially reasonable efforts to maintain the confidentiality of such Confidential Information). Except for indemnification of copyright and trade secret claims, the indemnification provisions of Section 10 shall not in any way apply to Feedback, Intels use of Feedback and/or LMI providing of Feedback. 3.3 No Other Licenses and Rights. Except as expressly provided in Section 3.1, no other license or right is granted to LMI to any Intel patents, copyrights, mask works, trade secrets, or other intellectual property under this Agreement, expressly or by implication, estoppel, statute or otherwise. Except as expressly provided in Section 3.2, no other license or right is granted to Intel to any LMI patents, copyrights, mask works, trade secrets, or other intellectual property under this Agreement, expressly or by implication, estoppel, statute or otherwise. 3.4 Ownership. Intel and/or its suppliers retain all right, title and interest in the Licensed Technology, as such are supplied by Intel and/or its suppliers under this Agreement, and all copies thereof, in whole or in part. Any Derived Code developed by LMI shall be owned by LMI, subject to Intels ownership to the Licensed Technology. LMI acknowledges Intels and its suppliers assertion of copyright, trademark, patent, trade secret and any other intellectual property rights in the Licensed Technology supplied by Intel and/or its suppliers under this Agreement. LMI and/or its suppliers retain all right, title and interest in the LMI Products, as such are supplied by LMI and/or its suppliers under this Agreement, and all copies thereof, in whole or in part. Intel acknowledges LMIs and its suppliers assertion of copyright, trademark, patent, trade secret and any other intellectual property rights in the LMI Products. 4. Royalty Fees. 4.1 Royalties for Host-based Access Products. In consideration for the license granted under Section 3, LMI agrees to pay Intel royalties as described on Exhibit C in connection with the sale by LMI of LMI Host-based Access Products that include a license to use the Licensed Technology. 4.2 Royalties for Console-based Access Products. In consideration for the license granted under Section 3, LMI agrees to pay to Intel royalties as described on Exhibit C , in connection with the sale by LMI of LMI Console-based Access Products that include a license to use the Licensed Technology. 4.3 Quarterly Report. Unless otherwise agreed by the parties in writing, within Intel Confidential 3

EXHIBIT E ATTRIBUTION AND USAGE GUIDELINES Intel Trademark Guidelines : The approved usage is: Intel Remote PC Assist Technology This name should be used in its complete form , exactly as shown above. Do not change the capitalization, unless used in a heading where normal capitalization rules apply. The mark Intel must always be used with this name, and the trademark symbol should follow Intel. No other trademark symbols (such as, , or SM ) or nouns should be used.

Intel Confidential 26

Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in this Amendment No. 9 to Registration Statement No. 333-148620 of our report dated February 19, 2009 (June 25, 2009 as to Note 16) (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the Companys adoption of Financial Accounting Standards Board Interpretation No. 48, Accounting for Uncertainty in Income Taxes, effective January 1, 2007), appearing in the Prospectus, which is a part of such Registration Statement, and to the reference to us under the heading Experts in such Prospectus. /s/ Deloitte & Touche LLP Boston, Massachusetts June 26, 2009

Appendices for West Herts PCT

PCT-Practice Agreement

Example 1 West Herts PCT.doc
Appendix 1 Summary of the GPSoC Services
Supplier : EMIS Product : EMIS LV Version : 5.2 Date Ordered : 29/07/2002 Planned Installation : 29/07/2002 Installed : 29/07/2002
Core Services GPSoC Level 2 Service GPSoC Level 3 Service Anticipated Actual Actual Service Business Go Business Go Deployment Commencement Live Live Verification
06/02/2008 06/02/2008 06/02/2008 06/02/2008 06/02/2008 06/02/2008 06/02/2008 06/02/2008
Appendix 2 Support & Maintenance Service Levels For the purpose of defining response times, the working hours are defined to be 08.00 to 17.00, Monday to Friday. Each fault logged with the Egton support team will be assigned a priority. The table below briefly indicates how each priority is assigned and which Service Level Agreement is invoked based on that assignment: Priority Level Critical Initial Response Time 30 minutes Initial Diagnosis 1 Working Hour Resolution 4 Working Hours (excluding critical faults caused by third party non supported systems) 8 Working Hours 2 Working Days As agreed
High Medium Low Definitions
1 Working Hour 2 Working Hours 4 Working Hours
6 Working Hours 8 Working Hours 16 Working Hours

Critical

Surgery System Down

Examples:

In this instance a surgery would have no access to their clinical system from any terminal No ability to print scripts throughout the surgery Loss of the use of email. No connection to NHS net
Note: Egton will endeavour to co-ordinate a solution within this time frame but will have to work within the constraints of the response from the surgeries clinical supplier and other third parties.
Where a surgery experiences loss of key functionality affecting many users

Examples

Loss of a key system scripts printer, loss of more than half of Desktop connectivity to the Local Area Network (LAN)

Medium

Where a surgery experience loss of functionality effecting one user General PC faults Single user Printer faults Scanner faults 3
Loss of the use of 1 PC or printer
Where the problem can be comfortably resolved using an alternative route. A low problem will involve loss of functionality on a level that does not disrupt the smooth running of the surgery and one where the surgery contact is happy to agree a response time
Contacting the Egton support team Each Managed service engineer will be supplied with a mobile phone, the number will be supplied to his/her allocated sites and they will be able to contact the engineer on this number.
Engineer Absents The engineer will place a message on his mobile phone indicating that he/she is not at work and supplying the Egton helpdesk number.
Egton Helpdesk The helpdesk will try to resolve issues over the phone, if this is not possible an engineer will be allocated from the local team. Sites are expected to assist in the diagnosis of issues
NB The PCT is currently tendering for the provision of a support and maintenance service for Primary Care. After the tender process is complete and service providers confirmed this appendix will be subject to change with fuller service levels outlined
Appendix 3 Escalation Procedure If a practice are not satisfied with any aspect of their ICT system or support, the Practice Manager should escalate to Shane Scott, the Primary Care ICT Manager. Telephone: ext 321 Mobile: Email: shane.scott@herts-pcts.nhs.uk

If a practice remains unsatisfied following a response from the Primary Care ICT Manager, the Practice Manager should escalate to Phil Crossley, Head of ICT/CIO Hertfordshire PCTs Telephone: Mobile: 07785716861 Email: phil.crossley@herts-pcts.nhs.uk
Following a response from The Head of ICT/CIO, if the practice is still not satisfied, the practices senior partner should escalate to Gareth Jones, Director of Strategic Commissioning Email: gareth.jones@herts-pcts.nhs.uk
For audit purposes, and clarity, escalation should be confirmed in written form
Appendix 4 Business Case for Migration of GP Clinical IT System
GPSoC Business Case Templatev1.0.d
GPSOC BUSINESS CASE FOR MIGRATION OF GP CLINICAL IT SYSTEM
PART A: PROCESS PART B: BUSINESS CASE TEMPLATE
PART A PROCESS FOR PRODUCING A BUSINESS CASE FOR MIGRATION 1. Trigger/requirement for a business case 1.1 a PCT may require the Practice to prepare a business case in the case of a Practice proposed change of system; or 1.2 NHS CFH may require the initiator of a proposed change of system to prepare a business case where NHS CFH is bearing some or all of the costs of migration and the ongoing costs for the new GP clinical IT system. A Business Case may be prepared for one or more Practices. 2. Example Drivers 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3. Improvements to patient care offered by alternative systems New system offered by existing supplier More suitable system available from another supplier Local health community IT requirements NHS and/or PCT IT strategy Existing system is not a GPSoC Compliant System Supplier ceases to support existing system Practice ownership Practice relationship with other practices changes
Process 3.1 Both the practice and the PCT contribute to a Business Case to determine whether there is a case for migration.
If the case for migration is approved, there will be a selection process involving all GP clinical IT systems on the market including LSP and ESP systems.
The selection process, to be undertaken only if there is an agreed decision to migrate from one GP clinical IT system to another, is set out in the GPSoC Framework Agreement and the GPSoC Step by Step Guide, both of which can be downloaded from www.nhsconnectingforhealth.nhs.uk/gpsoc.
Detailed actions in respect of the Business Case 4.1 4.2 The Practice requests a system migration. The PCT, at its discretion or acting on behalf of NHS CFH, requests that the practice prepares a Business Case to justify the proposed system migration. 4.3 The PCT and Practice nominate lead individuals to develop the Business Case. 4.4 4.5 4.6 4.7 Both parties provide input in accordance with the template below The Practice drafts recommendation. The PCTs approval (or not) recorded. If the both parties agree, proceed with the selection process and migration as required. 4.8 If either party disagrees, then resolve the dispute in accordance with the provisions of clause 6 (Escalation and Dispute Resolution) of the PCTPractice Agreement.

PART B TEMPLATE BUSINESS CASE Item Strategic Fit Fit with National IT Strategy Considerations Assessment PCT View

Practice View

Fit with integrated patient care strategy Practice Considerations Existing system
The list of systems suitable for consideration including GPSoC Compliant Systems and LSP systems. Dependent on local policy Performance of the existing system or supplier. The roadmap for the practices existing system and the suppliers track record of delivery. Sharing patient information within a local health community and across care settings. e.g. plans for services offered, practice mergers, etc. Migration activities Migration timescales Typical bedding in period Associated risks
Clinical benefits of preferred position
Practices business strategy Impact of system and data migration
System Choice Assessment of available systems
Current status of available systems Supplier roadmaps Differences between the
Considerations practices existing system and other available systems

Assessment PCT View

Plans for migration to a hosted system Financial Implications Cost to the PCT

Cost to the practice

Order of magnitude incremental costs that will be incurred by PCT over 4 yr period as a result of migration: Infrastructure Deployment charges Service/ charges Support and training Order of magnitude incremental costs that will be incurred by the Practice over 4 yr period as a result of migration: Backfill for migration activities New peripheral equipment Availability of PCT project management resource to support the migration Availability of Practice resource for: Project management Data migration Training User system tests
Management Considerations PCT resource availability
Practice resource availability
Recommendation (drafted by THE Practice) The Practice will be required to make a recommendation which draws on the input material provided above. There are no prescribed weightings or scoring sheets as this is a matter for local discussion and determination, based on the Practice(s) and PCTs particular circumstances.
RECORD OF PCT APPROVAL PCT approves/does not approve* the planned migration (* delete as appropriate) PCT to insert rationale for decision here.
Signed on behalf of PCT Print Name. Date
Appendix 5 List of Prohibited Software and Hardware
Amendment History: Version Date 0.1 08/2008 0.2 08/09/2008 0.21 10/09/2008
Amendment History Initial draft Redrafted following comments from LMC Minor amendments following further comments from LMC
This is a list of software and hardware that the Practice should not install on the Practices IT infrastructure pursuant to clause Error! Reference source not found.
Hardware A list of all hardware currently funded by the PCT can be found at the end of this appendix. The following hardware should not be installed without prior agreement from the PCT:

Ref. Hardware 1 Any secondary switch or hub not forming part of the designed Infrastructure
Reason Compromises support with IT Support organisation* Degradation of network speed
Any PC or Laptop not equipped with the authorised Anti- Security risk Virus application
Any PC or Laptop with prohibited Software installed
(i) Compromises support with IT Support organisation. (ii) Degradation of main business applications (iii) Security risk
Any PC or Laptop not compliant with the agreed build regarding Hardware, Operating System or Application Software
Compromises SLA with IT Support organisation Degradation of network speed Security risk
Any device compromising the security of the Local Network
Any device compromising the performance of the Local Network
Degradation of main business applications Security risk Breach of IGSoC, Patient Confidentiality, Network integrity
Any device allowing access to unauthorised areas of the Domain by a 3rd Party granted limited authorised access to restricted areas of the Domain
Software The following software is not provided as standard with the operating system on the practice desktop configuration and will not be subsequently installed without justification, risk analysis and agreement from the PCT. Please note, the PCT wishes to work with practices and requests will not be unreasonably refused. Whilst we cannot provide a full support service for some software e.g. finance/accounts packages we will continue to provide best efforts where required.
Ref. Software 1 Media players**(e.g. iTunes, Winamp)
Reason Compromises support with IT Support organisation

Games**

Potential degradation of PC performance

Screensavers

(i) Potential degradation of PC performance (ii) Potential software conflicts (iii) Security risk regarding virus attack

Unlicensed software

(i) Copyright infringement (ii) Security risk
Peer to peer file sharing software (e.g. P2P, Limewire, Bearware, Emule, BitTorrent clients) 3rd Party Firewalls or the activation of the MS Firewall included with XP SP2
Security risk Breach of confidentiality Breach of IGSoC
Compromises support with IT Support organisation Potential degradation of support, software conflicts
Anti-virus software that has not been approved by the PCT
(i) Security risk (ii) Compromises support with IT Support organisation
Anti-spyware software that has not been approved by the PCT
(i) Security risk (ii) Compromises support with IT Support organisation (iii) Degradation of service

Unsolicited toolbars (e.g. Google toolbar, Yahoo, MSN)
Compromises support with IT

Support organisation

Alternative web browsers (e.g. Firefox, Opera)
Compromises support with IT Support organisation Does not function with NPfIT solutions
Digital camera software that has not been approved by the PCT
Compromises support with IT Support organisation Security risk Breach of IGSoC
Any form of remote access/control software (Logmein, Away From My Desk ([note waiting for central guidance])
Voice over IP software (e.g. Skype)
Compromises support with IT Support organisation Breach of IGSoC
Chat software (e.g. MSN Messenger, Yahoo messenger)
Compromises support with IT Support organisation Breach of IGSoC, Breach of code of conduct
Hand held devices software that has not been approved by the PCT
Any registry editing tools
Compromises support with IT Support organisation
Any software designed to transfer, or capable of transferring data to external portable storage devices without Encryption and not approved by the PCT.

Security risk

*Installing additional hardware or software will use more of your PCs memory and processing power. It is highly likely that this will result in a degradation of performance of your business applications.
**Except versions supplied with the Microsoft Windows Operating System.
The above list is not exhaustive and the PCT may add to or remove items from this list, in consultation with practices, at any time. When a new version of the list is produced the PCT will issue the latest version to all practices.
If unauthorised hardware or software is encountered on a PC during support activities then, in order to complete the support activity, we may need to remove the unauthorised hardware or software on that PC.
Process for Requesting Authorisation from the PCT If the Practice has a genuine business requirement to install software, other than that which is provided by the PCT, authorisation from the PCT must first be granted. To request authorisation from the PCT please follow the process detailed below. Requests will not be unreasonably refused. 1. Raise a call with the relevant helpdesk as referred to in Appendix 2 2. Provide details of the software type, name and version. 3. Provide details of which workstation(s) the software is to be installed on. 4. The helpdesk will log the request and issue an incident number. 5. The call will be forwarded to the engineer. 6. The engineer will assess the suitability of the software, in relation to the software types listed on the above exclusion list and the environment onto which it is to be installed. 7. If the software is deemed to be suitable for installation the engineer will install accordingly (See Additional Information 1 below). 8. If the software is deemed to be unsuitable the engineer will provide the necessary guidance required to ensure the Practice can make alternative arrangements (for example, the Practice may need to purchase additional memory, choose an alternative workstation or a different software version).

Additional information

1. The Practice must be responsible for providing the original copies of the software to be installed and all appropriate licences. No software will be installed where valid licences cannot be produced.
2. For those Practices wishing to install the software themselves, following authorisation from the PCT, they may do so although the PCT strongly recommends that your support provider undertakes all software installs.
3. The PCT will treat each request for software installation on a case by case basis and may not be able to provide ongoing support for the installed software. Where ongoing support cannot be provided by the PCT it is the responsibility of the Practice to arrange this and cover any associated costs for such support.
Funded Hardware The following is a current list of funded hardware. This list may well change, in consultation with practices, over a period of time as new equipment becomes standard practice equipment.

Category

Items Funded PC Workstations

Items Not Funded

Comments As supplied as part of the ongoing Replacement Programme

Workstation

TFT Monitor
17 is current standard, we are not actively replacing 15 TFTs at this time

Standard Keyboards

As part of a new/replacement PC

Other Keyboards

E.g. Natural Keyboards, Bluetooth Cordless Keyboards, Internet Keyboards etc. Unless there is a valid reason.

Standard Mouse

Other Mice/Pointing Devices
E.g. Graphics Tablets, Light Pens, Trackballs, Bluetooth Cordless mice etc. Unless there is a valid reason.

Internal CD ROM Drives

Backup Devices, CD Writers etc
Used for backing up documents and other data on workstations. The preferred method for backing these up is to store them centrally and hence include them in the main system backup, but it may be that practices do not (or cannot) want payroll/accounts data etc stored on a central server. This will be limited to only one or two devices per practice. Associated media for backup devices Consumables.

Clinical Servers Server

Maintained through Clinical Supplier contract.

Monitors

Comments as for Workstation monitors

Keyboards

Comments as for Workstation keyboards
Comments as for Workstation pointing devices

Internal CD ROM drives

CD or DVD Writer
Servers are backed up to TSU, or as per clinical suppliers recommendations.

Blank CDs/DVDs

Consumables.

Tape Streamers

Backup Tapes
UPSs (Uninterruptible Power Supplies)
MS Exchange or Other IPM Email Other Computers Servers (Breakdown as for Clinical servers)
Suitable alternatives are on offer via NHS mail so these could be phased out. A practice that wishes to maintain it's own E-Mail server of this type can therefore do so only at their own expense.
Thin Client/Branch Servers (Breakdown as for Clinical servers) Clinical Comms Servers (Breakdown as for PC workstations) Document Servers (Breakdown as for PC workstations)
These are usually higher spec than a workstation and need to run a server rather than a workstation Operating System For clinical messaging, e.g. Torex Connect servers, which are usually a similar spec to a workstation.
For document management systems such as Docman.
PC Workstations etc at a Member of If a machine was purchased by a practice specifically Staffs Home, Used Specifically For Practice Business/Dial-in etc. (Breakdown as for PC workstations) Laptops Portable for this type of use then this could be an issue.

Laptop Docking Stations

Palmtops/Handhelds
Palmtops with an Integrated Mobile Phone Mobile Phones/Pagers etc

Palmtop Docking Stations

Printer/Scanner Scanners Printers
Funded on basis of 1 per 7,500 list size With the exception of Dispensary label printers these should be Cut sheet only, e.g. Laserjet only

Dual tray printers.

Standard to support C&B and EPS.

Colour printers

Part funded if part of rationalization of printers within a practice Combined Scanner/Printers Part funded if part of rationalization of printers within practice

Photocopiers

The distinction between some photocopiers, combination scanner/printers and combination fax/scanner/printers is sometimes blurred. Generally we would consider a photocopier to be an administrative tool and not an IT tool. See also Fax machines.
Toner, Drum, Fuser, Ink Cartridges, Consumables. Printer Ribbons etc Digital Camera

Media Cards for Digital Cameras

Projectors

Network Switches

Network Routers

There should be no need for a practice to have a router except to route IP traffic off site. NHS Net routers are currently owned and maintained by BT (or C&W etc) so do not need to be included. The only

Network

possible exception is routers for branch connections, but, when N3 starts roll out, branches will be provided with a suitable NHS Net connection which will also be supported by BT or other third party. Fixed Network Cabling

Network Wall Points

Network Patch Panels WIFI Wireless Network Devices Funded only as part of new practice development schemes, only cabling infrastructure to support is included. Actual WiFi components only subject to business case approved by PCT. Cables KVM Switches For sharing a single keyboard, monitor and mouse with several machines (servers only)

General cables

Power cables, printer cables, USB cables, serial cables, Network Flyleads, KVM cables etc. Specialist Cables Mouse/Keyboard/monitor extensions, firewire cables, gender changers etc. Modems There is no longer any need to have a modem on site.

Telephone Systems

With IP telephone systems becoming common the technologies obviously overlap with other areas of IT. Advice available on procurement

Fax Machines

A practice may use a modem and fax software on a PC to handle faxes, and you can also get fax machines that can be used as scanners or printers, but generally we would consider a Fax machine to be an administrative tool and not an IT tool. See also Photocopiers.
Heart Monitor, BP Monitor, and other There are many of this type of machine about that Clinical Clinical hardware. connect to a USB or serial port of a workstation and enable stored readings and information to be uploaded into software for analysis. Miscellaneous Appointments Callboards

Sound Cards/Speakers

Currently not necessary for clinical work, but in the future these could be used for remote consultations/network meetings etc.

Webcams

As above

Bar Code Readers

These may be part of prescribing in future, currently not funded
Mouse Mats, Wrist Rests Monitor Stands, Printer Stands, Disk Boxes, Disk Drive Locks, etc Disks, Zip Disks, any other media.

Office furniture.

Batteries including re-chargeables for laptops, palmtops, digital cameras, mobile phones and other portable devices.